Randomized, Phase 2 Trial: Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Children Aged 2–17 Years
18 Mar, 2020 | 09:47h | UTCSafety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial – The Lancet (link to abstract – $ for full-text)